0000899243-19-006913.txt : 20190308 0000899243-19-006913.hdr.sgml : 20190308 20190308163238 ACCESSION NUMBER: 0000899243-19-006913 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190306 FILED AS OF DATE: 20190308 DATE AS OF CHANGE: 20190308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DUFFY MICHAEL P CENTRAL INDEX KEY: 0001237200 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 19669536 MAIL ADDRESS: STREET 1: C/O POINT THERAPEUTICS INC STREET 2: 125 SUMMER STREET SUITE 1840 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-06 0 0001521036 Lantheus Holdings, Inc. LNTH 0001237200 DUFFY MICHAEL P C/O LANTHEUS HOLDINGS, INC. 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 0 1 0 0 See Remarks Common Stock 2019-03-06 4 S 0 1789 22.769 D 160221 D Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.58 to $23.04, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. SVP, General Counsel and Secretary /s/ Michael P. Duffy 2019-03-08